Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study - Concepedia

Concepedia

Publication | Closed Access

Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study

82

Citations

21

References

2023

Year

William J. Sandborn, Silvio Danese, Jarosław Leszczyszyn, Jacek Romatowski, Engin Altıntaş, Elena Peeva, Mina Hassan‐Zahraee, Michael S. Vincent, Padmalatha S. Reddy, Christopher Banfield,

Clinical Gastroenterology and Hepatology

Gastrointestinal PharmacologyPhase 2BModerate-to-severe Ulcerative ColitisPharmacologyGastroenterologyOral RitlecitinibUlcerative ColitisMedicine

References

	Year	Citations

Page 1

Page 1